2022 World Conference on Lung Cancer (ePosters)-EP08.04-005. Phase II Study of Ramucirumab and Docetaxel for NSCLC Patients with Malignant Pleural Effusion

Pdf Summary

This study aimed to evaluate the safety and efficacy of administering ramucirumab (RAM) and docetaxel (DTX) to patients with non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE) who had received prior platinum-based therapy. Thirteen patients were enrolled in the study, and the pleural effusion control rate at 8 weeks was high. Only one case required thoracentesis during the treatment period. MPE decreased in 38.5% of cases, but the objective response rate (ORR) was low compared to previous studies. However, progression-free survival (PFS) was longer than in previous studies. There was a discrepancy between ORR and PFS, which may be attributed to pharmacodynamics and the small sample size of the study. Overall survival (OS) data was limited and immature. No grade 5 adverse events (AEs) occurred, and RAM and DTX showed a tolerable safety profile. This combination therapy holds promise for NSCLC patients with MPE who have previously received platinum-based therapy. The analysis included 13 cases, as two cases were excluded due to recently being enrolled in the study. Further analysis is planned. The study concludes that RAM and DTX show promise as a combination therapy for NSCLC patients with MPE, with a tolerable safety profile and potential efficacy. The study was funded by Eli Lilly Japan K.K. The most common adverse events reported were anemia, neutropenia, anorectal infection, anorexia, constipation, dyspnea, edema limbs, pleural effusion, febrile neutropenia, herpes simplex infection, insomnia, mucositis oral, and pneumonitis. The study also provided abbreviations for important terms used, such as NSCLC, MPE, DTX, RAM, VEGF, ECOG PS, RECIST, CTCAE, AD, SQ, Pleo, ICI, and DCR.

Asset Subtitle

Shinnosuke Takemoto

Meta Tag

Speaker Shinnosuke Takemoto

Topic Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

Keywords

ramucirumab

docetaxel

non-small cell lung cancer

malignant pleural effusion

platinum-based therapy

pleural effusion control rate

progression-free survival

objective response rate

overall survival

combination therapy